Asia-Pacific Glaucoma Treatment Market Information, by Disease Indication (Closed Angle Glaucoma (CAG), Open Angle Glaucoma (OAG), Secondary Glaucoma, Congenital Glaucoma and Other), Drug class (Prostaglandin Analogs (PGAs), Alpha Agonist, Beta Blockers, Cholinergic Drugs, Carbonic Anhydrase Inhibitors, and Others), Surgery (Laser Iridotomy, Laser Trabeculoplasty, Aqueous Shunt Surgery and Peripheral Iridectomy) and by End Users (Hospitals and Home Users) - Forecast till 2023
Pune, India -- (SBWIRE) -- 09/06/2018 -- Market Insights-Asia Pacific:
Market Research Future (MRFR) has revealed in its recently published report that the Asia Pacific glaucoma treatment market is set to expand at a robust CAGR of 7.5% during the forecast period. The market is estimated to reach a valuation of USD 888.94 Mn by 2023 up from USD 576 Mn in 2017. The wide prevalence of the disease is one of the key factors favoring the glaucoma treatment market proliferation in the Asia Pacific.
According to research published by the World Health Organization (WHO), glaucoma is the second most common cause of blindness across the world after cataract. The exponential geriatric population is at a higher risk of being affected by the disease. This has intensified the demand for effective treatment and increased research & development in the market. Furthermore, the rising burden of diabetes is poised to favor the market growth.
Get Sample Copy @ https://www.marketresearchfuture.com/sample_request/2962
The developments introduced in the treatment of glaucoma over the last few years have further opened avenues of growth opportunities for the market players. Other factors responsible for the Asia Pacific glaucoma treatment market growth are booming healthcare sector, increased healthcare expenditure, rising preventive measures, increasing awareness, etc.
By disease indication, the Asia Pacific glaucoma treatment market has been segmented into Closed Angle Glaucoma (CAG), open angle glaucoma (OAG), secondary glaucoma, congenital glaucoma and others.
By drug class, the glaucoma treatment market in Asia Pacific is segmented into Prostaglandin Analogs (PGAs), alpha agonist, beta blockers, cholinergic drugs, carbonic anhydrase inhibitors, and others.
By surgery, the Asia Pacific glaucoma treatment market has been segmented into laser iridotomy, laser trabeculoplasty, aqueous shunt surgery and peripheral iridectomy.
By end-users, the glaucoma treatment market in Asia Pacific is segmented into hospitals and home users.
The level of development of the healthcare sector in Asia Pacific varies from country to country. However, the eye care has been neglected in the region over the years. With the advent of developments in drug and diagnosis coupled with the availability of expertise with rich experience, the eye care market is set to grow saliently. The large-scale prevalence of glaucoma is likely to capitalize on the expanding eye care market. Japan and South Korea are estimated to lead the glaucoma treatment market in the region. Meanwhile, China is projected to exhibit a relatively higher rise in the market proliferation. Furthermore, the presence of strong generics in countries such as India is poised to catalyze the market size of glaucoma drugs market. This, in turn, is anticipated to aid glaucoma treatment market proliferation.
Apply for Exclusive Discount @ https://www.marketresearchfuture.com/check-discount/2962
Some of the key players profiled by MRFR in the report are Novartis AG, Pfizer Inc., Ocular Therapeutix Inc, Allergan, Merck & Co., pSivida Corp, Amorphex Therapeutics LLC., Ellex, Quantel, Icon Bioscience Inc, Lumenis, and Lightmed.
In April 2018, Chinese drugmaker Kanghong has finished the first step of the deal to run the China operations of Israeli glaucoma-treatment-developer IOPtima Ltd.
Send An Enquiry @ https://www.marketresearchfuture.com/enquiry/2962
About Market Research Future
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.